New hope for advanced breast cancer: targeted drug combo under trial
NCT ID NCT06057610
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests a new drug called SHR-A1811, given alone or with pertuzumab, against the standard treatment (trastuzumab, pertuzumab, and docetaxel) in 868 women with HER2-positive breast cancer that has returned or spread. The goal is to see if the new approach can delay cancer growth and improve survival. Participants must be aged 18-75, have measurable tumors, and be in good overall health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-A1811 (a targeted drug) with or without pertuzumab
- What this could lead to
- If successful, this could offer a new, more effective treatment option for people with HER2-positive breast cancer that has returned or spread.
- What could go wrong
- This is an early-stage trial, and the new drug may not work better than existing treatments or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVERECURRENT OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, 210029, China